Australian investors have spent much of 2026 trying to work out how to get exposure to artificial intelligence without simply buying a handful of overpriced American mega-caps. A recent screen published through Yahoo Finance points to one answer that is closer to home: a small cluster of ASX-listed companies that fold machine learning into medical software, imaging and diagnostics, and that are posting revenue growth of up to 38%.
The piece is a stock screen rather than a company announcement, which matters for how it should be read. It filters the local market for healthcare businesses that both describe themselves as using AI and are growing their top line quickly, then lists three names that clear the bar. That kind of article is less a verdict on any single company than a snapshot of where momentum is building, and right now a meaningful slice of that momentum sits in Australian health technology.
The context behind the numbers
Healthcare has long been one of the more credible places to put AI to work. Hospitals and clinics generate enormous volumes of structured and unstructured data, from scans and pathology results to clinical notes, and the pay-off from automating even part of that workload is tangible. Faster reporting, fewer missed findings and more efficient triage all translate fairly directly into revenue for the vendors who supply the software, which is why growth rates in the sector can run well ahead of the broader market.
A revenue growth figure approaching 38% is the sort of number that gets attention in a year when many investors have grown wary of companies that talk about AI without showing it in the accounts. The attraction of a screen like this one is that it insists on both: a genuine AI angle and actual sales growth. For retail investors in particular, who cannot easily buy into privately held local healthtech, the ASX names offer a listed, liquid way to take a position in a theme that has otherwise been dominated by offshore giants.
Two ways to read it
The optimistic case is straightforward. Australia has produced a string of respected medical-imaging and clinical-software businesses, and the global market for AI-assisted diagnostics is expanding quickly. Companies that are already selling into hospitals here and overseas have a running start, with recurring software revenue, sticky institutional customers and regulatory approvals that are hard for newcomers to replicate. On that view, strong revenue growth is the early signal of a durable franchise rather than a passing fad.
The more cautious reading starts with the nature of the screen itself. Revenue growth measured as a percentage can look spectacular when a company is working off a small base, and it says nothing about whether the business is profitable, how much cash it is burning, or how dependent it is on a single large contract. Several Australian healthtech names have delivered eye-catching growth one year and stumbled the next when a key customer paused spending or a product rollout slipped. Screens are a useful starting point, but they are a filter, not a recommendation, and the companies that appear in them can carry very different risk profiles despite sharing a headline growth rate.
There is also a broader market question hanging over the sector. With warnings about an AI valuations running hot globally, a company that trades on its AI credentials can be swept up in a wider repricing even if its own fundamentals are sound. That cuts both ways for the local names: it can inflate their multiples in a bull run and punish them disproportionately if sentiment turns.
What it means for Australia
Beyond the trading screens, the real story here is about where Australian capital and talent are flowing. The country has a genuine depth of expertise in medical imaging, diagnostics and clinical informatics, built on decades of strong research hospitals and a universal health system that produces rich data. If listed AI healthcare businesses can keep growing revenue at these rates, they give domestic investors a reason to fund the sector locally rather than watch the best ideas migrate to larger overseas markets in search of capital.
That has consequences well beyond the share register. A healthier pool of listed healthtech supports local jobs in engineering, clinical research and regulatory affairs, and keeps intellectual property anchored in Australia at a time when governments are openly worried about sovereign capability in critical technologies. It also feeds back into the hospitals themselves, because vendors that are growing can invest more in the tools that clinicians actually use day to day.
The flip side is the regulatory and safety backdrop that any Australian AI healthcare business now has to navigate. The sector has already felt the weight of this, with the Therapeutic Goods Administration’s treatment of AI medical scribes emerging as a real commercial hurdle for some operators, and clinicians at institutions such as St Vincent’s publicly pressing for a more confident national approach to healthcare AI. Revenue growth is only sustainable if the products behind it can satisfy regulators and win the trust of the doctors and nurses relying on them, and that is a slower, less glamorous race than the one playing out on the market screens.
What is next
The near-term test will be the next round of results and guidance from the listed players. Investors who have been drawn in by growth figures will want to see margins improving, cash burn under control and contracts converting into recurring revenue rather than one-off wins. Any sign that a headline growth rate was flattered by a single deal is likely to be punished quickly in a jittery market.
For readers tempted to act on a screen like this one, the sensible approach is the unglamorous one: treat it as a prompt to do the work, not a shortcut past it. The three names flagged may well prove to be among the better ways for Australians to back homegrown AI in healthcare, but the label on the list matters far less than the balance sheet, the pipeline and the regulatory standing underneath it. On that, the market will have plenty more to say in the months ahead.
Sources: Yahoo Finance.
